Michael is co-founder of T-CURX, main inventor of all of T-CURX patents, Chief Medical Officer and member of T-CURX’ Scientific Advisory Board. Michael is a clinician by training and an expert in the research and development of CAR T cell technologies and products. He is a treating physician in the Department of Internal Medicine II headed by world-renowned Prof. Einsele at the University Hospital Würzburg. Before joining Prof. Einsele’s Department at the University of Würzburg in 2012, Michael completed 3 years of postdoctoral research in Prof. Stan Riddell’s group at Fred Hutch Cancer Research in Seattle, WA, U.S.., a pioneer in adoptive immunotherapy and CAR T cell development and co-founder of JUNO Therapeutics Inc a leader in the CAR T cell field.

Michael studied medicine at the University of Leipzig, Germany, where he subsequently worked as a physician in internal medicine/hematology-oncology. Throughout his medical training, Michael performed laboratory research on the T cell-mediated graft-versus-leukemia effect in bone marrow transplantation under the supervision of Prof. Dr. Dietger Niederwieser, and graduated with honors in 2007, after which he started his postdoctoral research at the Fred Hutch.

Michael is an internationally renowned expert in adoptive cellular and CAR T cell-based cancer therapies and has published more than 60 peer-reviewed papers in the field. In addition, he is co-inventor on more than 10 patent applications in the field of cellular immunotherapy and CAR technology, which form the basis for T-CURX products and technologies.